The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumab
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase II trial (NCT02846623) of venetoclax, obinutuzumab and atezolizumab in patients with Richter’s transformation, an aggressive form of chronic lymphocytic leukemia (CLL) that is currently an area of unmet medical need. A total of 7 patients are currently enrolled and all patients achieved remission after treatment, with 3 patients proceeding to undergo allogeneic stem cell transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
